Drug Profile
Valganciclovir - Roche
Alternative Names: Cymeval; R127; RG 127; RO 1079070/194; RS 079070194; RS 79070; TA-9070; Valcyte; Valgancyclovir; ValixaLatest Information Update: 19 Jul 2022
Price :
$50
*
At a glance
- Originator Roche
- Developer Mitsubishi Tanabe Pharma Corporation; Roche; Stanford University School of Medicine; Vanderbilt University Medical Center
- Class Antivirals; Hypoxanthines; Small molecules
- Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cytomegalovirus infections; Cytomegalovirus retinitis
- No development reported Chronic fatigue syndrome
- Discontinued Ulcerative colitis
Most Recent Events
- 30 Jun 2022 Preregistration for Cytomegalovirus infections (In infants, In neonates) in Japan (PO)
- 30 Jun 2022 Valganciclovir - Roche receives Orphan Drug status for Cytomegalovirus infections in Japan
- 27 May 2022 Stanford University completes a phase I/II trial in Chronic fatigue syndrome in the US (NCT00478465)